CLINICAL IMMUNOLOGY
Common variants in IL-1RN, IL-1β and TNF-α and the risk of ovarian cancer: a case control study
More details
Hide details
Submission date: 2016-02-10
Final revision date: 2016-05-31
Acceptance date: 2016-06-03
Publication date: 2017-08-08
Cent Eur J Immunol 2017;42(2):150-155
KEYWORDS
ABSTRACT
Aim of the study: Several studies implicated altered inflammatory response in the susceptibility to ovarian cancer, and polymorphisms in inflammatory cytokines were shown to play an important role in the development of malignancies, including ovarian cancer (OC). Here we investigated the relationship between polymorphisms in IL-1 (-511C>T), IL-1RN VNTR, TNF- (-308G>A), and TNF RII (-322 VNTR) and OC risk in Tunisian women.
Methods and results: Study subjects comprised 62 OC patients and 126 healthy women. Genotyping was done from genomic DNA obtained from blood simple by PCR. Positive association between IL-1RN (-VNTR) A1 allele (p = 0.0069; OR = 2.04; 95% CI:1.17-3.58) and OC risk, while negative association was seen with the A3 allele (P = 0.0034; OR = 0.09; 95% CI: 0.00-0.64), suggesting a protective role by the A3 allele. For IL-1 (-511C>T), homozygous C/C genotype was associated with significantly increased risk of OC (p = 0.0002; OR = 4.14; 95% CI: 1.77-9.76), while heterozygote C/T genotype was linked with reduced risk of OC (p = 0.0033; OR = 0.40; 95% CI: 0.20-0.78). Furthermore, TNF- -308A allele was significantly associated with heightened risk of OC (p = 0.016; OR = 1.70; 95% CI: 1.08-2.69), and homozygote G/G genotype was associated with decreased risk of OC (p = 0.0018; OR = 0.25; 95% CI: 0.09-0.66). In contrast, TNFRII (-322 VNTR) polymorphism was not associated with altered OC risk in the studied group.
Conclusions: The significant association between IL-1RN VNTR, IL1- (-511), TNF- (-308) and OC susceptibility in Tunisian women confirms a role for altered inflammatory response in ovarian cancer pathogenesis.
REFERENCES (32)
1.
Brucks J (1992): Ovarian cancer. The most lethal gynecologic malignancy. Nurs Clin North Am 27: 835-845.
2.
Yigit R, Massuger LF, Figdor CG, Torensma R (2010): Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117: 366-372.
3.
Macciò A, Madeddu C (2012): Inflammation and ovarian cancer. Cytokine 58: 133-147.
4.
Balkwill F, Mantovani A (2001): Inflammation and cancer: back to Virchow? The lancet 357: 539-545.
5.
Haukim N, Bidwell J, Smith A, et al. (2002): Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 3: 313-330.
6.
Dinarello CA (1998): Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16: 457-499.
7.
Gaur U, Aggarwal BB (2003): Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003; 66: 1403-1408.
8.
Warlé MC, Farhan A, Metselaar HJ, et al. (2003): Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transplant 9: 170-181,.
9.
Wilson AG, Symons JA, McDowell TL, et al. (1997): Effects of a polymorphism in the human tumor necrosis factor promoter on transcriptional activation. Proc Natl Acad Sci U S A 94: 3195-3199.
10.
Nicklin MJ, Weith A, Duff GW (1994): A physical map of the region encompassing the human interleukin-1, interleukin-1, and interleukin-1 receptor antagonist genes. Genomics 19: 382-384.
11.
Zhang Y, Liu C, Peng H, Zhang J, Feng Q (2012): IL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: a literature review and meta-analysis. PLoS One 7: e46017.
12.
Xu J, Yin Z, Cao S, et al. (2013): Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS One 8: e63654.
13.
Zidi S, Stayoussef M, Zouidi F, et al. (2015): Tumor Necrosis Factor Alpha ( 238/ 308) and TNFRII-VNTR ( 322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians. Pathol Oncol Res 21: 339-345.
14.
Xie H, Yao H, Huo Y, Li N, Cheng Y (2014): Association between TNF- gene 308G> A polymorphism and lung cancer risk: a meta-analysis. Tumor Biol 35: 9693-9699.
15.
Shen C, Sun H, Sun D, et al. (2011): Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 126: 763-770.
16.
Chen Z, Zhu L, Zhang J, et al. (2013): TNF--308 G> A polymorphism and colorectal cancer risk: a meta-analysis. Int J Colorect Dis 1-2.
17.
Lu P, Tang Y, Li C, et al. (2010): Meta-analysis of association of tumor necrosis factor alpha-308 gene promoter polymorphism with gastric cancer. Zhonghua Yu Fang Yi Xue Za Zhi 44: 209-214.
18.
Yang Y, Luo C, Feng R, Bi S (2011): The TNF-, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 137: 947-952.
19.
Ahmed AB, Zidi S, Ghazouani E, et al. Research Article Interleukin-1 Receptor Antagonist VNTR Polymorphism and Ovarian Cancer Susceptibility in Tunisian Women.
20.
Braicu EI, Mustea A, Toliat MR, et al. (2007): Polymorphism of IL-1, IL-1 and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients. Gynecol Oncol 104: 680-685.
21.
Hefler LA, Ludwig E, Lebrecht A, et al. (2002): Polymorphisms of the interleukin-1 gene cluster and ovarian cancer.
22.
J Soc Gynecol Investig 9: 386-390.
23.
Bushley AW, Ferrell R, McDuffie K, et al. (2004): Polymorphisms of interleukin (IL)-1, IL-1, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 95: 672-679.
24.
Sehouli J, Mustea A, Koensgen D, et al. (2003): Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer. Ann Oncol 14: 1501-1504,.
25.
Zeng ZR, Hu PJ, Hu S, et al. (2003): Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut 52: 1684-1689.
26.
Perrey C, Turner SJ, Pravica V, et al. (1999): ARMS-PCR methodologies to determine IL-10, TNF-, TNF- and TGF-1 gene polymorphisms. Transplant Immunol 7 (2): 127-128.
27.
Keen L, Wood N, Olomolaiye O, Bidwell J (1999): A bi-allelic VNTR in the human TNFR2 (p75) gene promoter. Genes Immun 1: 164-165.
28.
Schrecengost A (2002): Ovarian Mass – Benign or Malignant? AORN J 76: 789-806,.
29.
Irvine KR, Rao JB, Rosenberg SA, Restifo NP (1996): Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156: 238-245.
30.
Corbacioglu S, Pietsch T, Koenig A, Welte K (1994): Interleukin-1 receptor antagonist: a powerful inhibitor of tumor vascularization and tumor growth in vivo. In VI International Symposium on Pediatric Neuro-Oncology, MD Anderson Cancer Center, Houston, TX 35.
31.
Hurme M, Santtila S (1998): IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1b genes. Eur J Immunol 28: 2598-2602.
32.
Ardizzoia A, Lissoni P, Brivio F, et al. (1991): Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6: 103-107.